MX2020007959A - Derivados de 2h-indazol e inhibidores de cdk4 y cdk6 y sus usos terapeuticos. - Google Patents
Derivados de 2h-indazol e inhibidores de cdk4 y cdk6 y sus usos terapeuticos.Info
- Publication number
- MX2020007959A MX2020007959A MX2020007959A MX2020007959A MX2020007959A MX 2020007959 A MX2020007959 A MX 2020007959A MX 2020007959 A MX2020007959 A MX 2020007959A MX 2020007959 A MX2020007959 A MX 2020007959A MX 2020007959 A MX2020007959 A MX 2020007959A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- therapeutic uses
- cdk4
- cyclin
- prodrugs
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 title 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract 3
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract 3
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 108091007914 CDKs Proteins 0.000 abstract 1
- 101000715943 Caenorhabditis elegans Cyclin-dependent kinase 4 homolog Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se divulgan compuestos 2H-indazol 2-aminopirimidina sustituidos de la fórmula (I), (ver Fórmula) donde R1 es hidrogeno y su profármaco, donde R1 es un grupo metabolizable en condiciones fisiológicas, como inhibidores de cinasa dependiente de ciclina (CDK) y de la proliferación celular y los usos terapéuticos y métodos de preparación de ellos. Estos compuestos y las sales farmacéuticamente aceptables, solvatos, profármacos y composiciones farmacéuticas de ellos, son útiles para el tratamiento de enfermedades y trastornos asociados con la actividad de las cinasas dependientes de ciclina, en particular CDK4/6, que incluyen en forma no taxativa diversos canceres y enfermedades o afecciones con la inflación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862623516P | 2018-01-29 | 2018-01-29 | |
| PCT/US2019/015547 WO2019148161A1 (en) | 2018-01-29 | 2019-01-29 | 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007959A true MX2020007959A (es) | 2020-09-18 |
Family
ID=67394794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007959A MX2020007959A (es) | 2018-01-29 | 2019-01-29 | Derivados de 2h-indazol e inhibidores de cdk4 y cdk6 y sus usos terapeuticos. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11352341B2 (es) |
| EP (1) | EP3746072B1 (es) |
| JP (1) | JP7337395B2 (es) |
| KR (1) | KR20200115583A (es) |
| CN (1) | CN111989099A (es) |
| AU (1) | AU2019211491B2 (es) |
| BR (1) | BR112020015405A2 (es) |
| CA (1) | CA3088381A1 (es) |
| EA (1) | EA202091450A1 (es) |
| IL (1) | IL275948A (es) |
| MX (1) | MX2020007959A (es) |
| PH (1) | PH12020551155A1 (es) |
| SG (1) | SG11202006748RA (es) |
| TW (1) | TW201940166A (es) |
| WO (1) | WO2019148161A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202000418XA (en) | 2017-07-18 | 2020-02-27 | Nuvation Bio Inc | Heterocyclic compounds as adenosine antagonists |
| EP3654982A4 (en) | 2017-07-18 | 2021-04-14 | Nuvation Bio Inc. | 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES |
| WO2019161224A1 (en) | 2018-02-15 | 2019-08-22 | GiraFpharma LLC | Heterocyclic compounds as kinase inhibitors |
| SG11202012312UA (en) * | 2018-06-18 | 2021-01-28 | UCB Biopharma SRL | Gremlin-1 antagonist for the prevention and treatment of cancer |
| CN113924095A (zh) | 2019-01-18 | 2022-01-11 | 诺维逊生物股份有限公司 | 作为腺苷拮抗剂的杂环化合物 |
| WO2020150676A1 (en) | 2019-01-18 | 2020-07-23 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| EP3917532A4 (en) * | 2019-01-29 | 2022-09-28 | Beta Pharma, Inc. | 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases |
| SG11202112229UA (en) | 2019-05-05 | 2021-12-30 | Qilu Regor Therapeutics Inc | Cdk inhibitors |
| CN115768763B (zh) * | 2020-06-22 | 2025-09-09 | 正大天晴药业集团股份有限公司 | 一种cdk4/6抑制剂的制备方法 |
| US20230416271A1 (en) * | 2020-11-26 | 2023-12-28 | Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. | Heteroarylquinazoline compounds as protein kinase inhibitors |
| TW202237585A (zh) | 2020-11-27 | 2022-10-01 | 瑞士商瑞森製藥公司 | Ｃｄｋ抑制劑 |
| WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL220952B1 (pl) | 2002-01-22 | 2016-01-29 | Warner Lambert Co | 2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony |
| ATE412650T1 (de) * | 2003-07-11 | 2008-11-15 | Warner Lambert Co | Isethionat salz eines selektiven cdk4 inhibitors |
| JPWO2006008874A1 (ja) * | 2004-05-21 | 2008-05-01 | 萬有製薬株式会社 | アミノチアゾ−ル骨格を有するＣｄｋ４、６選択的阻害剤 |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| US9259399B2 (en) * | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
| PE20110419A1 (es) * | 2008-08-22 | 2011-07-13 | Novartis Ag | Compuestos de pirrolo-pirimidina como inhibidores de cdk |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| ES2687477T3 (es) * | 2013-12-31 | 2018-10-25 | Xuanzhu Pharma Co., Ltd. | Inhibidor de quinasa y su uso |
| TWI675028B (zh) | 2014-07-24 | 2019-10-21 | 美商貝達醫藥公司 | 做為週期素依賴型激酶（ｃｄｋ）抑制劑之2-ｈ-吲唑衍生物及其醫療用途 |
| JP6726677B2 (ja) * | 2015-03-11 | 2020-07-22 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. | 抗がん剤としての置換２−ｈ−ピラゾール誘導体 |
| CN107286134B (zh) * | 2016-04-11 | 2019-04-12 | 上海勋和医药科技有限公司 | 2，4-二取代嘧啶衍生物作为cdk抑制剂及其应用 |
-
2019
- 2019-01-29 CA CA3088381A patent/CA3088381A1/en not_active Abandoned
- 2019-01-29 KR KR1020207024587A patent/KR20200115583A/ko not_active Withdrawn
- 2019-01-29 WO PCT/US2019/015547 patent/WO2019148161A1/en not_active Ceased
- 2019-01-29 CN CN201980010752.7A patent/CN111989099A/zh active Pending
- 2019-01-29 US US16/965,376 patent/US11352341B2/en active Active
- 2019-01-29 AU AU2019211491A patent/AU2019211491B2/en active Active
- 2019-01-29 EA EA202091450A patent/EA202091450A1/ru unknown
- 2019-01-29 JP JP2020562086A patent/JP7337395B2/ja active Active
- 2019-01-29 TW TW108103389A patent/TW201940166A/zh unknown
- 2019-01-29 SG SG11202006748RA patent/SG11202006748RA/en unknown
- 2019-01-29 EP EP19743187.7A patent/EP3746072B1/en active Active
- 2019-01-29 BR BR112020015405-9A patent/BR112020015405A2/pt not_active Application Discontinuation
- 2019-01-29 MX MX2020007959A patent/MX2020007959A/es unknown
-
2020
- 2020-07-09 IL IL275948A patent/IL275948A/en unknown
- 2020-07-29 PH PH12020551155A patent/PH12020551155A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200115583A (ko) | 2020-10-07 |
| US11352341B2 (en) | 2022-06-07 |
| JP2021512161A (ja) | 2021-05-13 |
| TW201940166A (zh) | 2019-10-16 |
| AU2019211491A1 (en) | 2020-07-30 |
| EP3746072A4 (en) | 2021-06-02 |
| WO2019148161A1 (en) | 2019-08-01 |
| JP7337395B2 (ja) | 2023-09-04 |
| PH12020551155A1 (en) | 2021-06-07 |
| AU2019211491B2 (en) | 2024-03-14 |
| CA3088381A1 (en) | 2019-08-01 |
| SG11202006748RA (en) | 2020-08-28 |
| BR112020015405A2 (pt) | 2020-12-08 |
| EP3746072B1 (en) | 2023-04-12 |
| EA202091450A1 (ru) | 2021-01-14 |
| CN111989099A (zh) | 2020-11-24 |
| US20210139459A1 (en) | 2021-05-13 |
| EP3746072A1 (en) | 2020-12-09 |
| IL275948A (en) | 2020-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551155A1 (en) | 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof | |
| PH12017500146A1 (en) | 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof | |
| JOP20220247A1 (ar) | مثبطات كرومينون تفارغية لفوسفوينوسيتيد 3 كيناز (pi3k) لعلاج أمراض مرتبطة بتعديل p13k | |
| PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| MX2023013080A (es) | Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades. | |
| AR066214A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. usos y composiciones farmaceuticas | |
| PH12020551494A1 (en) | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors | |
| NZ708563A (en) | Treatment of cancers using pi3 kinase isoform modulators | |
| NO20051265L (no) | Anvendelse av og noen nye imidazopyridiner | |
| TW201613593A (en) | Molecules for administration to ROS1 mutant cancer cells | |
| JP2010527981A (ja) | 癌処置用のｃｈｋ阻害剤およびｐａｒｐ阻害剤の組み合わせ剤 | |
| PH12013501594A1 (en) | Substituted indazole derivatives active as kinase inhibitors | |
| MY141220A (en) | Pyrazole derivatives as inhibitors of receptor tyrosine kinases | |
| MX2024013178A (es) | Inhibidores alostericos de cromenona de la fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades | |
| SA523451700B1 (ar) | (pi3k) مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز لعلاج السرطان | |
| SG11201806438UA (en) | Fused Pyrazole Derivatives, Preparation Method Thereof, And Use Thereof In Treatment Of Cancers, Inflammation And Immune Diseases | |
| GB201302704D0 (en) | Therapeutic compounds | |
| MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof | |
| MX2024015817A (es) | Inhibidores de la cinasa dependiente de ciclina 2 para tratamiento medico | |
| TW202402282A (zh) | 咪唑啉酮衍生物在製備用於聯合放療治療腫瘤的藥物中的應用 | |
| MX2024014626A (es) | Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton | |
| AU2020278236A8 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
| CL2019002601A1 (es) | Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos. | |
| NZ761680A (en) | Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors |